CJC-1295 doses in the published research — what was administered, by which route, and for how long it lasted.

Doses used in the published research

CJC-1295 dosage in the controlled human record is narrow. The pharmacokinetic studies administered single subcutaneous doses of 30, 60, or 90 micrograms per kilogram of body weight in healthy volunteers ^[1][3]. There is no approved human dose, no titration schedule, and no maintenance regimen in the peer-reviewed literature — the human work was designed to characterize GH and IGF-1 kinetics, not to establish a therapeutic dose.

In animal work, the GHRH-knockout-mouse growth study used a fixed 2-microgram dose per administration at 24-, 48-, or 72-hour intervals ^[4]. The microgram-per-kilogram human doses and the fixed microgram mouse doses are the only dosing figures grounded in published studies.

The fixed-dose figures circulating in community and clinic "protocols" — commonly cited in the 100-to-300-microgram range for no-DAC Modified GRF (1-29) and for CJC-1295/ipamorelin pairings — are not derived from controlled human trials ^[8]. This site logs what the studies used; it does not convert that into a use instruction.

Route and half-life

Subcutaneous injection was the primary route in the published research; early GRF(1-29) pharmacokinetic work also used intravenous administration ^[1][2]. Oral bioavailability is negligible because CJC-1295 is a peptide, so the oral route does not appear in the dosing record.

Half-life is where the two variants diverge most sharply. The DAC variant's half-life was estimated at 5.8 to 8.1 days in healthy adults, with IGF-1 elevation persisting up to 28 days after multiple doses ^[1]. The no-DAC form, Modified GRF (1-29), is short-acting — minutes to hours — because it lacks the albumin-binding handle and clears at roughly the rate of native GHRH(1-29) with protease-resistant substitutions ^[1][11]. A dose figure means very different things depending on which variant it describes, which is why the DAC vs no-DAC distinction matters before any dosing number does.

Research handling and stability

In laboratory handling, the lyophilized peptide is reconstituted with bacteriostatic water and refrigerated ^[8]. The four amino-acid substitutions confer resistance to DPP-IV and other proteases, and in the DAC variant the albumin conjugation is what confers the multi-day duration of action ^[1][2]. These notes describe how the research material is stored and prepared in a laboratory context; they are not preparation instructions for use.

The distinction between a handling description and a use protocol is the line this page holds. CJC-1295 is an unapproved research chemical; the published record characterizes its pharmacokinetics, not a safe human regimen.

How much CJC-1295 should I take?

There is no approved human dose. Published human pharmacokinetic studies used single subcutaneous doses of 30, 60, or 90 micrograms per kilogram in research settings ^[1][3]. Online "protocols" are not derived from controlled human trials, and CJC-1295 is unapproved for human use.

How much CJC-1295 DAC should I take?

No approved human dose exists. Human pharmacokinetic work with the DAC variant used 30 to 90 micrograms per kilogram subcutaneously ^[1][3]; its multi-day half-life of 5.8 to 8.1 days means exposure persists far longer than the short-acting no-DAC form ^[1].

How to reconstitute CJC-1295?

In research handling the lyophilized peptide is reconstituted with bacteriostatic water and refrigerated ^[8]. Oral bioavailability is negligible; subcutaneous injection is the route used in studies ^[1]. This is descriptive of laboratory handling, not a use instruction.

Where to inject CJC-1295?

Published research used subcutaneous injection as the primary route; early GRF(1-29) pharmacokinetic work also used intravenous administration ^[1][2]. The literature describes the route studied; it does not establish a safe human-use protocol.